Plain-English translation of NCT06590324 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a new medication designed to reduce inflammation and other processes in the body that may contribute to long COVID symptoms. You would take this medication twice daily by mouth (with meals) for up to 12 weeks, alongside a diabetes medication called dapagliflozin that you may already be taking. The study aims to see if this treatment can improve how long COVID affects your daily life and your overall health.
Long COVID can cause serious, lasting symptoms in people with diabetes, and there are currently few proven treatments that target the underlying causes. This trial is testing whether this medication could address the inflammation and damage associated with long COVID, offering a new option for people struggling with this condition.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic 7 times over about 12 weeks for check-ups and assessments. At your first visit, you would sign consent forms and have screening tests (blood work, pregnancy test if applicable, COVID-19 test). Once approved, you would start taking the medication twice daily at home with meals. During clinic visits, the study team would monitor your symptoms, check your health, and gather information about how the treatment is working for you.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Jordan
Saudi Arabia
United Arab Emirates